Lek's Sales Revenues Soar by 52 Percent

Ljubljana, 2 February - The Ljubljana-based pharmaceuticals maker Lek upped its sales revenues by 51.9 percent to SIT 145 billion (EUR 610m) last year, subscribing importantly to the results posted by Sandoz, the generics unit of Lek's majority owner Novartis. The bulk of revenues, SIT 139bn (EUR 586m) was generated by the parent company Lek, the chairman Metod Dragonja told the press on Monday.